11.94
0.09 (0.72%)
| Penutupan Terdahulu | 11.85 |
| Buka | 11.83 |
| Jumlah Dagangan | 465,442 |
| Purata Dagangan (3B) | 5,815,527 |
| Modal Pasaran | 8,150,196,736 |
| Harga / Jualan (P/S) | 354.33 |
| Harga / Buku (P/B) | 1.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -4,823.84% |
| EPS Cair (TTM) | -0.750 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.93% |
| Nisbah Semasa (MRQ) | 33.47 |
| Aliran Tunai Operasi (OCF TTM) | -839.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -375.20 M |
| Pulangan Atas Aset (ROA TTM) | -10.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Roivant Sciences Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.88 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 30.31% |
| % Dimiliki oleh Institusi | 83.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Patient Square Capital Lp | 31 Mar 2025 | 12,480,000 |
| Julat 52 Minggu | ||
| Median | 18.00 (50.82%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Jun 2025 | 18.00 (50.82%) | Beli | 11.44 |
| 28 May 2025 | 18.00 (50.82%) | Beli | 10.62 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |